Boston-area CRO Integral BioSystems Announces Tradeshow Presence at Key Pharmaceutical Conferences

The Boston-area formulation development CRO Integral BioSystems, LLC announces tradeshow presence at key pharmaceutical and biotech conferences, as part of its strategy to increase visibility.
Spread the Word
Listed Under

Drug Delivery
Drug Development
Formulation Development


Massachusetts - US

May 17, 2011 - PRLog -- Integral BioSystems, a contract research organization in the Boston area announced today that it intends to show-case its capabilities and expertise at key pharmaceutical conferences in 2011. This is part of Integral BioSystems’ strategy to enhance its visibility as a company that offers expertise in formulation development and subsequent CMC development.

In this capacity, Integral Biosystems, LLC has already attended the Society for Biomaterials 2011 and the ARVO 2011 meetings, held in April and May, 2011.  Integral BioSystems intends to attend the AAPS conference in Oct, 2011.  

The company specializes in the design and development of dosage forms for ophthalmic, transdermal, intravenous, intranasal and oral routes of drug administration. Furthermore, the company offers intellectual property and contracts development/negotiation services.

About Integral BioSystems, LLC

Integral BioSystems, LLC was founded in 2008 by experienced drug development and patent professionals. The company has adopted a translational medicinal approach to drug development, customizing delivery systems to accomplish the biologically effective objectives of the therapy.  Delivery systems are customized to achieve sustained release or targeted, tissue-focused delivery, or fast-release/instant delivery, depending upon the desired product attributes.

Once the drug-containing formulations are tested in preclinical models, an integrated CMC plan is developed to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept.  The company has a network of manufacturers / analytical houses for pharmaceutics, that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.

David Karasic
Chief Intellectual Property and Business Development Officer
Integral BioSystems, LLC

# # #

A boston area-based contract research organization, Integral BioSystems specializes in the development of ophthalmic, transdermal, intravenous, intranasal and oral dosage forms. Additionally, we offer services in intellectual property and contracts.
Source:Dave Karasic, J.D.
Email:*** Email Verified
Account Email Address Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share